Frontier Medicines will present its first Phase 1 clinical findings for FMC-376 at ESMO 2026, including preliminary responses in patients previously treated with KRAS G12C inhibitors. The investigational drug targets both active and inactive KRAS G12C, but detailed response rates and patient counts remain undisclosed ahead of the presentation.
A peer-reviewed validation study found that patients with high OncoPrism-NSCLC scores had a 71% response rate to checkpoint inhibitor-based treatment, compared with 36% in lower-scoring groups. The analysis included 1,487 patients across four datasets, although the prospective clinical utility of using the test to choose treatment remains unproven.
Circulating tumor DNA can detect molecular traces of residual cancer after apparently curative treatment, but proving that acting on an earlier signal improves survival is the harder challenge.
Antibody-drug conjugates combine targeting antibodies with powerful cytotoxic payloads, but clinical performance increasingly depends on linker chemistry, drug-to-antibody ratio, payload properties and how the medicine behaves inside heterogeneous tumors.
Explore how Sanyou Bio and Baiyunshan Xihe are combining AI discovery and nuclear medicine to advance precision oncology theranostics.
See how One Biosciences is using single-cell profiling to improve ADC biomarkers, patient selection and future companion diagnostics.
Find out how Verastem Oncology’s VS-7375 trial could reshape KRAS G12D pancreatic cancer treatment and what risks remain.
Find out how AstraZeneca’s Truqap approval could reshape PTEN-deficient prostate cancer treatment and biomarker testing.
Find out how Phinomics is using circular DNA and explainable AI to reshape oncology discovery and cancer biomarker research.
Find out how Guardant360 CDx approval could expand liquid biopsy use in HER2-mutant advanced lung cancer treatment selection.